<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606511</url>
  </required_header>
  <id_info>
    <org_study_id>S-20200094</org_study_id>
    <nct_id>NCT04606511</nct_id>
  </id_info>
  <brief_title>Lymphedema Screening</brief_title>
  <acronym>LymphScreen</acronym>
  <official_title>Screening for Lymphedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer-related lymphedema is one of the most common and feared consequences of breast&#xD;
      cancer treatment. Currently, there is no established screening program for lymphedema. This&#xD;
      cross-sectional study will investigate diagnostic modalities in screening for lymphedema in&#xD;
      patients with and without known lymphedema after breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity, specificy, NPV and PPV</measure>
    <time_frame>through study completion, approximately 1 year</time_frame>
    <description>diagnosotic statistics of lymphedema measurements</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Breast cancer patients with lymphedema</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer patients without lymphedema</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Circumference tape measurements</intervention_name>
    <description>centimeter and volume criterias</description>
    <arm_group_label>Breast cancer patients with lymphedema</arm_group_label>
    <arm_group_label>Breast cancer patients without lymphedema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Indocyanine green lymphangiography</intervention_name>
    <description>Presence of dermal backflow</description>
    <arm_group_label>Breast cancer patients with lymphedema</arm_group_label>
    <arm_group_label>Breast cancer patients without lymphedema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bioimpedance spectroscopy</intervention_name>
    <description>7.5 and 10 L-DEX criterias</description>
    <arm_group_label>Breast cancer patients with lymphedema</arm_group_label>
    <arm_group_label>Breast cancer patients without lymphedema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Symptom score</intervention_name>
    <description>using lymph-icf, DASH and SF-36 questionnaires</description>
    <arm_group_label>Breast cancer patients with lymphedema</arm_group_label>
    <arm_group_label>Breast cancer patients without lymphedema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous breast cancer treated with axillary lymph node dissection&#xD;
&#xD;
          -  No recurrence&#xD;
&#xD;
          -  Understand the study&#xD;
&#xD;
          -  Can talk, read and understand Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Lymph node dissection from other basins&#xD;
&#xD;
          -  Psychiatric disorder&#xD;
&#xD;
          -  Not possible to perform indocyanine green lymphangiography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mads G Jørgensen, MD</last_name>
    <phone>29210114</phone>
    <phone_ext>+45</phone_ext>
    <email>Mads.Gustaf.Jorgensen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Plastic and Reconstructive Surgery</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads G Jørgensen, MD</last_name>
      <email>Mads.Gustaf.Jorgensen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jens A Sørensen, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mads Gustaf Jørgensen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>5 years after study completion</ipd_time_frame>
    <ipd_access_criteria>Upon reasonable request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

